Transgene Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Alessandro Riva

Chief Executive Officer (CEO)

€304.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	6.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Alessandro Riva (62 yo)

less than a year

Permanencia

€304,000

Compensación

Dr. Alessandro Riva, M.D., serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2023. He serves as Independent Non-Executive Director at BeiGene, Ltd. since February 01...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alessandro Riva	CEO & Chairman of the Board	less than a year	€304.00k	sin datos
Lucie Larguier	Chief Financial Officer	less than a year	sin datos	sin datos
Eric Quemeneur	Executive VP & Chief Scientific Officer	no data	sin datos	sin datos
John Felitti	VP, General Counsel & Corporate Secretary	8.2yrs	sin datos	sin datos
Christelle Schwoerer	Chief Human Resources Officer	less than a year	sin datos	sin datos
Maud Brandely-Talbot	VP of Medical Affairs & Chief Medical Officer	8.2yrs	sin datos	sin datos
James Wentworth	VP & Chief Business Officer	less than a year	sin datos	sin datos
Gaelle Stadtler	VP & Director of Human Resources	no data	sin datos	sin datos
Kaidre Bendjama	Project Leader of Personalized Cancer Vaccines	no data	sin datos	sin datos
Elisabetta Castelli	Director of Investor Relations	no data	sin datos	sin datos
Cécile Razimbaud	Corporate Communication & Investor Relation	no data	sin datos	sin datos

0.6yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TGNA no se considera experimentado ( 0.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alessandro Riva	CEO & Chairman of the Board	2yrs	€304.00k	sin datos
Benoit Habert	Independent Director	24.3yrs	€34.00k	0.074% € 98.7k
Alain Merieux	Honorary Chairman	4.3yrs	sin datos	60.2% € 80.3m
Philippe Archinard	Director	19.4yrs	sin datos	0.56% € 748.7k
Christopher Walker	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jean-Claude Weill	Member of Scientific Advisory Board	no data	sin datos	sin datos
Rafick-Pierre Sekaly	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Santo	Member of Scientific Advisory Board	no data	sin datos	sin datos
Pierre Coulie	Member of Scientific Advisory Board	no data	sin datos	sin datos
Marie-Yvonne Landel-Meunier	Independent Director	6.9yrs	€53.00k	sin datos
Maya Said	Independent Director	6.9yrs	€75.00k	sin datos
Sandrine Flory	Director	3.3yrs	sin datos	sin datos

6.9yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de TGNA se considera experimentada (6.8 años de antigüedad promedio).

Transgene Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Transgene SA Announces Chief Financial Officer Changes

Transgene SA Appoints Carol Stuckley as Independent Director

Transgene SA Approves Board and Committee Changes

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

Recent updates

Full year 2023 earnings released: €0.22 loss per share (vs €0.33 loss in FY 2022)

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

New major risk - Financial position

New minor risk - Share price stability

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Full year 2022 earnings released: €0.33 loss per share (vs €0.21 loss in FY 2021)

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue misses expectations

New 90-day high: €2.84

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

New 90-day high: €2.69

New 90-day high: €2.60

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.74

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

First half 2020 earnings released: €0.03 loss per share

New 90-day high: €1.57

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

Transgene SA to Report Fiscal Year 2009 Results on 03/22/2010

First half earnings released

New 90-day low - €1.33

A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million.

Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG).

Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA.

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad